← All trials
NCT04912076
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 17, 2018
- Primary completion
- Mar 22, 2019
- Completion date
- Mar 22, 2019
- First posted
- Jun 3, 2021
- Last posted
- Jun 3, 2021
- Enrollment
- 47
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Southern DenmarkLead sponsor
- University of AmsterdamCollaborator
- University of Southern DenmarkReponsible party - principal investigator
- European CommissionCollaborator
- University of SalzburgCollaborator
- University of Southern DenmarkOverall official - principal investigator
- Biomay AGCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.